Blood-Brain Barrier Leakage Linked to Alzheimer's Pathology in Middle Age

Alzheimer's disease (AD) and cerebrovascular disease rarely operate in isolation — most dementia cases in older adults involve both pathologies. Yet the biological mechanisms linking vascular dysfunction to AD progression remain poorly understood, particularly during midlife when vascular exposures may exert their greatest influence on long-term brain health. This study from Columbia University's Taub Institute addressed this gap by investigating whether plasma biomarkers of blood-brain barrier (BBB) permeability link cerebrovascular lesions to AD pathophysiology in middle-aged adults.

Researchers enrolled 488 participants (mean age 54.3 years; 67% women) from the Offspring Study of Racial and Ethnic Disparities in Alzheimer's Disease, a community-based cohort in northern Manhattan. Participants underwent 3T MRI brain imaging and plasma biomarker profiling. Three vascular cognitive impairment (VCI) biomarkers reflecting pathologic angiogenesis and BBB dysfunction were measured using the Meso Scale Discovery platform: PlGF, VEGF-D, and bFGF. Alzheimer's-related plasma biomarkers — amyloid-beta ratio (Aβ42/40), phosphorylated tau 181 (p-tau181), GFAP (astrocytosis), and neurofilament light chain (NfL, neurodegeneration) — were measured via Simoa immunoassays. White matter hyperintensity (WMH) volumes were derived from FLAIR MRI sequences.

Key findings emerged from both bivariate correlations and path analyses. PlGF was positively associated with older age, greater WMH volume, and higher GFAP, p-tau181, and NfL concentrations. VEGF-D was associated with higher GFAP and NfL. bFGF showed an inverse association with the Aβ42/40 ratio and a positive association with p-tau181. Path modeling revealed the best-fitting causal sequence: PlGF indirectly elevates GFAP (astrocytic neuroinflammation) through its effect on WMH burden. GFAP then directly drives p-tau181, which in turn predicts NfL — a downstream marker of neurodegeneration. This cascade suggests that BBB permeability promotes white matter damage, which fuels neuroinflammation, tau pathology, and ultimately neuronal injury.

These results are clinically significant because they position BBB dysfunction as an early, modifiable upstream event in the AD pathophysiological cascade — preceding overt amyloid or tau accumulation in many individuals. The midlife window may be especially important: vascular risk factors and BBB compromise during this period could initiate neuroinflammatory processes that accelerate AD decades later. PlGF, VEGF-D, and bFGF represent accessible plasma biomarkers that could eventually serve as screening tools or therapeutic targets for early vascular-AD pathway intervention.

Important caveats apply. The study is cross-sectional, so causal inferences from path analysis remain provisional. The cohort is racially and ethnically diverse but geographically concentrated in northern Manhattan, which may limit generalizability. Plasma VEGF biomarkers reflect systemic angiogenesis and are not brain-specific. Longitudinal studies are needed to confirm whether elevated BBB permeability markers in midlife prospectively predict AD biomarker changes and cognitive decline.